Carcinoid Syndrome Management Market Research Report Information, by organs affected (Small Intestine, Lungs, Rectum, Appendix, Colon, Stomach, Pancreas, Liver and others) by Treatment (Chemotherapy, Biological therapy, and Hepatic Artery Embolization Agents), by End users (Hospital, Clinics, Cancer institute and treatment centers) Forecast to 2030
ID: MRFR/MED/2100-HCR | 85 Pages | Author: Rahul Gotadki | May 2023
Table of Contents
1 INTRODUCTION
1.1 DEFINITION
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.2.2.1 ASSUMPTIONS
1.2.2.2 LIMITATIONS
1.3 MARKET STRUCTURE:
2 RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:
3 MARKET DYNAMICS
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 MACROECONOMIC INDICATORS
4 MARKET FACTOR ANALYSIS
4.1 PORTERS FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY
5 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY ORGANS AFFECTED
5.1 SMALL INTESTINE
5.2 RECTUM
5.3 LUNGS
5.4 APPENDIX
5.5 COLON
5.6 STOMACH
5.7 PANCREAS
5.8 LIVER
5.9 OTHERS
6. GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY TREATMENT TYPE
6.1 CHEMOTHERAPY
6.3 BIOLOGICAL THERAPY
6.4 HEPATIC ARTERY EMBOLIZATION AGENT
7. GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY END USERS
7.1 HOSPITALS
7.2 CLINICS
7.3 CENCER INSTITUTIONS AND TREATMENT CENTERS
7.4 OTHERS
8. GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY REGION
8.1 NORTH AMERICA
8.1.1 INTRODUCTION
8.2 EUROPE
82.1 INTRODUCTION
8.3 ASIA-PACIFIC
8.3.1 INTRODUCTION
8.4 MIDDLE EAST & AFRICA
8.4.1 INTRODUCTION
9. COMPETITIVE LANDSCAPE
9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
9..1.1 STRATEGIC PARTNERSHIP
10..1.2 MERGER & ACQUISITION
10 COMPANY PROFILE
10.1 BTG INTERNATIONAL LTD.
10.1.1 OVERVIEW
10.1.2 PRODUCT OVERVIEW
10.1.3 FINANCIALS
10.1.4 KEY DEVELOPMENTS
10.2 IPSEN BIOPHARMACEUTICALS, INC.,
10.2.1 OVERVIEW
10.2.2 PRODUCT OVERVIEW
10.2.3 FINANCIALS
10.2.4 KEY DEVELOPMENTS
10.3 NOVARTIS INTERNATIONAL AG (SANDOZ)
10.3.1 OVERVIEW
10.3.2 PRODUCT OVERVIEW
10.3.3 FINANCIALS
10.3.4 STRATEGY
10.3.5 KEY DEVELOPMENT
10.4 PHARMASCIENCE INC.,
10.4.1 OVERVIEW
10.4.2 PRODUCT OVERVIEW
10.4.3 FINANCIALS
10.4.4 KEY DEVELOPMENTS
10.5 TEVA PHARMACEUTICAL INDUSTRIES LTD.
10.5.1 OVERVIEW
10.5.2 PRODUCT OVERVIEW
10.5.3 FINANCIALS
10.5.4 KEY DEVELOPMENTS
10.6 OTHERS
List of Tables
TABLE 1 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY ORGANS AFFECTED, 2020-2027 (USD MILLION)
TABLE 2 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 3 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKETBY END USERS 2020-2027 (USD MILLION)
TABLE 4 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY REGION 2020-2027 (USD MILLION)
List of Figures
FIGURE 1 RESEARCH PROCESS
FIGURE 2 PORTERS FIVE FORCES MODEL
FIGURE 3 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY ORGANS AFFECTED
FIGURE 4 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY TREATMENT TYPE
FIGURE 5 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY END USERS
FIGURE 6 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY REGION
FIGURE 7 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
Leading companies partner with us for data-driven Insights.
